Eiger BioPharmaceuticals Inc
F:72C1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Eiger BioPharmaceuticals Inc
F:72C1
|
US |
|
Semac Consultants Ltd
BSE:505368
|
IN |
|
S
|
Structural Monitoring Systems PLC
F:RJP
|
AU |
|
GNI Group Ltd
F:3G6
|
JP |
|
R
|
Ross Group PLC
F:8SS
|
UK |
|
Kooth PLC
F:KO0
|
UK |
|
N
|
Nevada Exploration Inc
F:28N
|
CA |
|
M
|
Matsui Securities Co Ltd
XMUN:MTW
|
JP |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 72C1's stock price target?
Not Available
72C1 does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Eiger BioPharmaceuticals Inc?
Projected CAGR
31%
The compound annual growth rate for Revenue over the next 3 years is 31%.